Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iva annua pollen extract is a non-standardized biological allergenic extract derived from the pollen of the *Iva annua* plant, commonly known as Annual Marsh-Elder or Rough Marsh Elder. It is primarily utilized in clinical practice for the diagnosis and treatment of Type I immediate hypersensitivity allergies. As a diagnostic tool, it is used in skin testing (percutaneous or intradermal) to identify patients sensitized to Marsh-Elder allergens by eliciting a localized IgE-mediated allergic response. As a therapeutic agent, it is used in allergen immunotherapy (hyposensitization), where gradually increasing doses are administered subcutaneously to induce immunological tolerance and reduce symptoms associated with allergic rhinitis or asthma. The product is manufactured by Greer Laboratories and is approved for use in the United States.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iva annua pollen extract.